Form 4 for WST West Pharmaceutical Services
Accepted 2024-08-08 00:00:00 ET · period of report 2024-08-06 · accession 0001127602-24-021894 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-08-08 | 2024-08-06 | WST | Green Eric Mark | Pres, CEO, Board COB, Dir | M - OptEx | $59.64 | +36.7K | 167.9K | +28% | +$2.19M |
| D | 2024-08-08 | 2024-08-06 | WST | Green Eric Mark | Pres, CEO, Board COB, Dir | S - Sale+OE | $304.71 | -30.7K | 161.9K | -16% | -$9.36M |
| DM | 2024-08-08 | 2024-08-06 | WST | Green Eric Mark | Pres, CEO, Board COB, Dir | M - OptEx | $0.00 | -36.7K | 6,000 | -86% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-06 | M | A | 30,732 | $59.64 | 192,640.12 | D | — | — | (F1) The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. |
| 2 | Common | Common Stock | 2024-08-06 | S | D | 30,732 | $304.71 | 161,898.12 | D | — | — | (F1) The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. (F2) The price reported in Column 4 is a weighted average price. |
| 3 | Common | Common Stock | 2024-08-06 | M | A | 6,000 | $59.64 | 167,898.12 | D | — | — | (F1) The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. |
| 4 | Derivative | Stock Option (Right to Buy) | 2024-08-06 | M | D | 6,000 | $0.00 | 0 | D | $59.64 · — to 2026-02-23 | 6,000 Common Stock | (F3) This option is fully vested. |
| 5 | Derivative | Stock Option (Right to Buy) | 2024-08-06 | M | D | 30,732 | $0.00 | 6,000 | D | $59.64 · — to 2026-02-23 | 30,732 Common Stock | (F3) This option is fully vested. |